The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
Open accessAbstract
The therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase 2b NEFIGAN trial. To verify these findings, the phase 3 NefigArd trial tested the efficacy and safety of nine months of treatment with Nefecon (16 mg/d) versus placebo in adult patients with primary IgAN at risk of progressing to kidney failure (ClinicalTrials.gov: NCT03643965). NefIgArd was a multicenter, randomized, double-blind, placebo-controlled two-part trial. In Part A, 199 patients with IgAN were treated with Nefecon or placebo for nine months and observed for an additional three months. The primary endpoint for Part A was 24-hour urine protein-to-creatinine ratio (UPCR) after nine months. Secondary efficacy outcomes evaluated included estimated glomerular filtration rate (eGFR) at nine and 12 months and the UPCR at 12 months. At nine months, UPCR was 27% lower in the Nefecon group compared with placebo, along with a benefit in eGFR preservation corresponding to a 3.87 ml/min/1.73 m 2 difference versus placebo (both significant). Nefecon was well-tolerated, and treatment-emergent adverse events were mostly mild to moderate in severity and reversible. Part B is ongoing and will be reported on later. Thus, NefIgArd is the first phase 3 IgA nephropathy trial to show clinically important improvements in UPCR and eGFR and confirms the findings from the phase 2b NEFIGAN study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Wyatt, R. J., & Julian, B. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206793 · Cited by 1,222
Intensive supportive care plus immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415463 · Cited by 726
Self-citationFellström, B. C., Barratt, J., Cook, H., Coppo, R., Feehally, J., de Fijter, J. W., Floege, J., Hetzel, G., Jardine, A. G., Locatelli, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30550-0 · Cited by 414
Self-citationHeerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30314-0 · Cited by 397
Self-citation
Cited by
Lafayette, R., Kristensen, J., Stone, A., Floege, J., Tesař, V., Trimarchi, H., Zhang, H., Eren, N., Paliege, A., Reich, H. N., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01554-4 · Cited by 337
Self-citationRovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D.-W., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02302-4 · Cited by 307
Self-citationThe pathogenesis of IgA nephropathy and implications for treatment
Cheung, C. K., Alexander, S., Reich, H. N., Selvaskandan, H., Zhang, H., & Barratt, J. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00885-3 · Cited by 222
Self-citationRovin, B. H., Barratt, J., Cook, H. T., Noronha, I. L., Reich, H. N., Suzuki, Y., Tang, S. C. W., Trimarch, H., & Floege, J. (2025) · Kidney International · doi:10.1016/j.kint.2025.04.004 · Cited by 206
Self-citationSibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
Perkovic, V., Trimarchi, H., Tesar, V., Lafayette, R., Wong, M. G., Barratt, J., Suzuki, Y., Liew, A., Zhang, H., Carroll, K., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2512133 · Cited by 90
Self-citation
Metadata
- Authors
- Barratt, J., Lafayette, R., Kristensen, J., Stone, A., Cattran, D., Floege, J., Tesar, V., Trimarchi, H., Zhang, H., Eren, N., Paliege, A., Rovin, B. H., Fragale, G., Karl, A., Losisolo, P., Trimarchi, H., Hoyos, I. G., Lampo, M. G., Monkowski, M., De La Fuente, J., Alvarez, M., Stoppa, D., Chiurchiu, C., Novoa, P. A., Orias, M., Barron, M. B., Giotto, A., Arriola, M., Cassini, E., Maldonado, R., Dionisi, M. P., Ryan, J., Toussaint, N., Luxton, G., Peh, C. A., Levidiotis, V., Francis, R., Phoon, R., Fedosiuk, E., Toropilov, D., Yakubtsevich, R., Mikhailova, E., Bovy, C., Demoulin, N., Hougardy, J.-M., Maes, B., Speeckaert, M., Laurin, L.-P., Barbour, S., Masse, M., Hladunewich, M., Reich, H., Cournoyer, S., Tennankore, K., Barbour, S., Lv, J., Liu, Z., Wang, C., Li, S., Luo, Q., Ni, Z., Yan, T., Fu, P., Cheng, H., Liu, B., Lu, W., Wang, J., Chen, Q., Wang, D., Xiong, Z., Chen, M., Xu, Y., Wei, J., Pai, P., Chen, L., Rehorova, J., Maixnerova, D., Safranek, R., Rychlik, I., Hruby, M., Makela, S., Vaaraniemi, K., Ortiz, F., Alamartine, E., Daroux, M., Cartery, C., Vrtovsnik, F., Serre, J.-E., Stamellou, E., Vielhauer, V., Hugo, C., Budde, K., Otte, B., Nitschke, M., Ntounousi, E., Boletis, I., Papagianni, A., Goumenos, D., Stylianou, K., Zermpala, S., Esposito, C., Cozzolino, M. G., Viganò, S. M., Gesualdo, L., Nowicki, M., Stompor, T., Kurnatowska, I., Kim, S. G., Kim, Y.-L., Na, K.-R., Kim, D. K., Kim, S.-H., Porras, L. Q., Garcia, E. R., Pamplona, I. A., Segarra, A., Goicoechea, M., Fellstrom, B., Lundberg, S., Hemmingsson, P., Guron, G., Sandell, A., Chen, C.-H., Tokgoz, B., Duman, S., Altiparmak, M. R., Ergul, M., Maxwell, P., Mark, P., McCafferty, K., Khwaja, A., Cheung, C. K., Hall, M., Power, A., Kanigicherla, D., Baker, R., Moriarty, J., Mohamed, A., Aiello, J., Canetta, P., Ayoub, I., Robinson, D., Thakar, S., Mottl, A., Sachmechi, I., Fischbach, B., Singh, H., Mulhern, J., Kamal, F., Linfert, D., Rizk, D., Wadhwani, S., Sarav, M., Campbell, K., Coppock, G., Luciano, R., Sedor, J., Avasare, R., & Lau, W. L.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 103
- Issue
- 2
- Pages
- 391-402
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W4306757577
- Cited by
- 224
- References
- 5
- FWCI
- 25.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. https://app.cochat.ai/papers/10.1016/j.kint.2022.09.017
- The paper
- Barratt, J., Lafayette, R., Kristensen, J., Stone, A., Cattran, D., Floege, J., Tesar, V., Trimarchi, H., Zhang, H., Eren, N., Paliege, A., Rovin, B. H., Fragale, G., Karl, A., Losisolo, P., Trimarchi, H., Hoyos, I. G., Lampo, M. G., Monkowski, M., . . . Lau, W. L. (2023). Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney International. https://doi.org/10.1016/j.kint.2022.09.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.